Evidence-Based Clinical Practice Guidelines Medical Therapy For Pulmonary Arterial Hypertension : ACCP

2004;126;35-62 Chest McCrory, Gerald Simonneau and Vallerie V. McLaughlin David B. Badesch, Steve H. Abman, Gregory S. Ahearn, Robyn J. Barst, Douglas C. Evidence-Based Clinical Practice Guidelines Medical Therapy For Pulmonary Arterial Hypertension: ACCP This information is current as of April 22, 2006 http://www.chestjournal.org/cgi/content/full/126/1_suppl/35S located on the World Wide Web at: The online version of this article, along with updated information and services, is ISSN: 0012-3692. may be reproduced or distributed without the prior written permission of the copyright holder. 3300 Dundee Road, Northbrook IL 60062. All rights reserved. No part of this article or PDF published monthly since 1935. Copyright 2005 by the American College of Chest Physicians, CHEST is the official journal of the American College of Chest Physicians. It has been

[1]  Eric J Carro-Jiménez,et al.  Primary pulmonary hypertension and pregnancy. , 2005, Boletin de la Asociacion Medica de Puerto Rico.

[2]  M. Humbert,et al.  Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. , 2003, American journal of respiratory and critical care medicine.

[3]  W. Seeger,et al.  Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. , 2003, American journal of respiratory and critical care medicine.

[4]  G. Funk,et al.  Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. , 2003, Chest.

[5]  R. Barst,et al.  Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension , 2003, Clinical pharmacology and therapeutics.

[6]  N. Pereira,et al.  Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. , 2002, The American journal of cardiology.

[7]  C. Narasimhan,et al.  A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. , 2002, Indian heart journal.

[8]  G. Simonneau,et al.  New treatments for pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[9]  W. Seeger,et al.  Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension , 2002, Annals of Internal Medicine.

[10]  E. Michelakis,et al.  Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension: Comparison With Inhaled Nitric Oxide , 2002, Circulation.

[11]  G. Verleden,et al.  Combined liver and (heart-)lung transplantation in liver transplant candidates with refractory portopulmonary hypertension. , 2002, Transplantation.

[12]  R. Speich,et al.  Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. , 2001, Swiss medical weekly.

[13]  B. Cairns,et al.  Inhaled Nitric Oxide for Primary Pulmonary Hypertension in Pregnancy , 2001, Obstetrics and gynecology.

[14]  G. Sybrecht,et al.  Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension , 2001, Circulation.

[15]  M. Humbert,et al.  Risk factors for pulmonary arterial hypertension. , 2001, Clinics in chest medicine.

[16]  B. Winters,et al.  Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[17]  L. Monnery,et al.  Primary pulmonary hypertension in pregnancy; a role for novel vasodilators. , 2001, British journal of anaesthesia.

[18]  N. Morrell,et al.  Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension , 2001, Circulation.

[19]  F. Narducci,et al.  Use of inhaled nitric oxide for emergency Cesarean section in a woman with unexpected primary pulmonary hypertension , 2001, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[20]  M. Uematsu,et al.  Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. , 2001, American journal of respiratory and critical care medicine.

[21]  G. Olson,et al.  Pregnancy and primary pulmonary hypertension : successful outcome with epoprostenol therapy. , 2001, Chest.

[22]  K. Bremme,et al.  Cesarean section under epidural ropivacaine 0.75% in a parturient with severe pulmonary hypertension , 2001, Acta anaesthesiologica Scandinavica.

[23]  A. Loeckinger,et al.  Sildenafil modulates hemodynamics and pulmonary gas exchange. , 2001, American journal of respiratory and critical care medicine.

[24]  H. Farber,et al.  Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. , 2000, American journal of respiratory and critical care medicine.

[25]  I. Khan,et al.  HIV-Related pulmonary hypertension: analytic review of 131 cases. , 2000, Chest.

[26]  P. Kuo,et al.  Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension. , 2000, Transplantation.

[27]  W. Hurford,et al.  Effects of Intravenous Zaprinast and Inhaled Nitric Oxide on Pulmonary Hemodynamics and Gas Exchange in an Ovine Model of Acute Respiratory Distress Syndrome , 2000, Anesthesiology.

[28]  W. Vogel,et al.  Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension. , 2000, Wiener klinische Wochenschrift.

[29]  R. Aubry,et al.  Twin pregnancy in a woman on long-term epoprostenol therapy for primary pulmonary hypertension. A case report. , 2000, The Journal of reproductive medicine.

[30]  R. Wiesner,et al.  Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension , 1999, Hepatology.

[31]  A. Atz,et al.  Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. , 1999, Anesthesiology.

[32]  A. Chaouat,et al.  Improvement of pulmonary hypertension after liver transplantation. , 1999, Chest.

[33]  S. Rich,et al.  Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series , 1999, Annals of Internal Medicine.

[34]  M. Landzberg,et al.  Inhaled nitric oxide therapy in pregnancy complicated by pulmonary hypertension. , 1999, American journal of obstetrics and gynecology.

[35]  G. Maislin,et al.  Vasodilator therapy for primary pulmonary hypertension in children. , 1999, Circulation.

[36]  P. Huang,et al.  The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. , 1999, The Journal of clinical investigation.

[37]  K.,et al.  Anaesthesia for caesarean section in the presence of severe primary pulmonary hypertension. , 1998, British journal of anaesthesia.

[38]  W R Clarke,et al.  Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. , 1998, American journal of respiratory and critical care medicine.

[39]  D. Ivy,et al.  Acute hemodynamic effects of pulsed delivery of low flow nasal nitric oxide in children with pulmonary hypertension. , 1998, The Journal of pediatrics.

[40]  J. W. Miller,et al.  Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. , 1998, American journal of respiratory and critical care medicine.

[41]  D. Ivy,et al.  Hemodynamic effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. , 1998, Chest.

[42]  O. Hess,et al.  Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. , 1998, Journal of the American College of Cardiology.

[43]  W R Clarke,et al.  Dipyridamole potentiates pulmonary vasodilation induced by acetylcholine and nitric oxide in the ovine fetus. , 1998, American journal of respiratory and critical care medicine.

[44]  D. Ivy,et al.  Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. , 1998, The Journal of thoracic and cardiovascular surgery.

[45]  M. Humbert,et al.  Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. , 1998, The European respiratory journal.

[46]  C. Howell,et al.  Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. , 1998, Transplantation.

[47]  R. D. Rudic,et al.  Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. , 1998, The Journal of clinical investigation.

[48]  E. Block,et al.  A Caveolar Complex between the Cationic Amino Acid Transporter 1 and Endothelial Nitric-oxide Synthase May Explain the “Arginine Paradox”* , 1997, The Journal of Biological Chemistry.

[49]  K. Maruyama,et al.  Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats. , 1997, Circulation.

[50]  A. Halbower,et al.  Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus. , 1997, The American journal of physiology.

[51]  J P Cooke,et al.  Nitric oxide synthase: role in the genesis of vascular disease. , 1997, Annual review of medicine.

[52]  C. Howell,et al.  Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. , 1997, Transplantation.

[53]  M. Petch,et al.  Aging-associated endothelial dysfunction in humans is reversed by L-arginine. , 1996, Journal of the American College of Cardiology.

[54]  J Benichou,et al.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.

[55]  W. Auger,et al.  Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. , 1996, Chest.

[56]  D. Schraufnagel,et al.  Structural and pathologic changes in the lung vasculature in chronic liver disease. , 1996, Clinics in chest medicine.

[57]  P. Ganz,et al.  Atherosclerosis: risk factors and the vascular endothelium. , 1996, American heart journal.

[58]  N. Voelkel,et al.  Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. , 1995, The European respiratory journal.

[59]  D. Stewart,et al.  Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. , 1995, Circulation.

[60]  S. Das,et al.  Nitric oxide: its identity and role in blood pressure control. , 1995, Life sciences.

[61]  R. Cohen,et al.  The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. , 1995, Progress in cardiovascular diseases.

[62]  J. Loscalzo,et al.  Nitric oxide and its role in the cardiovascular system. , 1995, Progress in cardiovascular diseases.

[63]  J. Canty,et al.  Modulation of coronary autoregulatory responses by endothelium-derived nitric oxide. , 1995, International journal of cardiology.

[64]  D. Harrison,et al.  Interactions between L-arginine and L-glutamine change endothelial NO production. An effect independent of NO synthase substrate availability. , 1995, The Journal of clinical investigation.

[65]  A. Quyyumi,et al.  Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. , 1995, Circulation.

[66]  D. Mitchell,et al.  AIDS and the lung: update 1995. 2. New developments in the pulmonary diseases affecting HIV infected individuals. , 1995, Thorax.

[67]  G. Pieper,et al.  Amelioration by L‐Arginine of a Dysfunctional Arginine/Nitric Oxide Pathway in Diabetic Endothelium , 1995, Journal of cardiovascular pharmacology.

[68]  J. Sandoval,et al.  Primary pulmonary hypertension in children: clinical characterization and survival. , 1995, Journal of the American College of Cardiology.

[69]  P. Bruni,et al.  Identification of a specific transport system for L-arginine in human platelets. , 1995, Biochemical and biophysical research communications.

[70]  T. Rector,et al.  Lack of contribution of nitric oxide to basal vasomotor tone in heart failure. , 1994, The American journal of cardiology.

[71]  S. Hohnloser,et al.  Elevated High-Density Lipoprotein Levels Ameliorate Abnormal Vasoconstriction in Early Atherosclerosis , 2005 .

[72]  R. Cramb,et al.  Pulmonary hypertension and pregnancy: a series of eight cases , 1994, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[73]  G. Simonneau,et al.  Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. , 1994, Circulation.

[74]  W. Paulus.  Endothelial control of vascular and myocardial function in heart failure , 1994, Cardiovascular drugs and therapy.

[75]  J. Stamler,et al.  Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. , 1994, Circulation.

[76]  K. Ivanova,et al.  Soluble Guanylyl Cyclase and Platelet Function a , 1994, Annals of the New York Academy of Sciences.

[77]  L. Raij,et al.  Glomerular thrombosis in pregnancy: role of the L-arginine-nitric oxide pathway. , 1994, Kidney international.

[78]  D. Hayoz,et al.  Endothelial dysfunction in chronic heart failure. Experimental and clinical studies. , 1994, Arzneimittel-Forschung.

[79]  W. Hurford,et al.  Inhaling nitric oxide: a selective pulmonary vasodilator and bronchodilator. , 1994, Chest.

[80]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[81]  L. Ruilope,et al.  161 Endothelium-dependent responses in fructose-induced hypertension , 1993 .

[82]  W. Vogel,et al.  Effects of repeated stress on plasma arginine levels in young and old rats , 1993, Physiology & Behavior.

[83]  D. Hayoz,et al.  Endothelial function in congestive heart failure. , 1993, American heart journal.

[84]  T. Evans,et al.  L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance. , 1993, British journal of clinical pharmacology.

[85]  J. Coligan,et al.  Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. , 1993, Journal of immunology.

[86]  J. Cooke,et al.  L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. , 1992, The Journal of clinical investigation.

[87]  H. Palevsky,et al.  Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. , 1992, The American review of respiratory disease.

[88]  J. Stamler,et al.  Endothelium‐Derived Relaxing Factor Modulates the Atherothrombogenic Effects of Homocysteine , 1992, Journal of cardiovascular pharmacology.

[89]  E. Bassenge.  Clinical relevance of endothelium-derived relaxing factor (EDRF). , 1992, British journal of clinical pharmacology.

[90]  H. Drexler,et al.  Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine , 1991, The Lancet.

[91]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[92]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[93]  J. Cooke,et al.  Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta , 1991, Circulation.

[94]  J. Cooke,et al.  L-arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. , 1990, Circulation research.

[95]  S. Abman,et al.  Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. , 1990, The American journal of physiology.

[96]  B. Groves,et al.  26. Pulmonary Hypertension Associated with Hepatic Cirrhosis , 1990 .

[97]  J. Bultinck,et al.  Pulmonary fat embolism presenting as chronic respiratory failure. , 1989, The European respiratory journal.

[98]  W. Edwards,et al.  Coexistent pulmonary and portal hypertension: morphologic and clinical features. , 1987, Journal of the American College of Cardiology.

[99]  S. Moncada,et al.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.

[100]  G. Stoltenburg‐Didinger,et al.  [Primary pulmonary hypertension in children]. , 1982, Zeitschrift fur Kardiologie.

[101]  P. Ogburn,et al.  Levels of free fatty acids and arachidonic acid in pregnancy and labor. , 1980, The Journal of laboratory and clinical medicine.

[102]  R. San Antonio,et al.  Laennec's cirrhosis and primary pulmonary hypertension. , 1980, American heart journal.

[103]  S. Sothy,et al.  Carbohydrate and lipid metabolism during human labor: free fatty acids, glucose, insulin, and lactic acid metabolism during normal and oxytocin-induced labor for postmaturity. , 1976, Metabolism: clinical and experimental.

[104]  A. Fishman.  Dietary Pulmonary Hypertension , 1974, Circulation research.

[105]  C. Wagenvoort,et al.  Primary Pulmonary Hypertension: A Pathologic Study of the Lung Vessels in 156 Clinically Diagnosed Cases , 1970 .

[106]  G. Kerr.  The Free Amino Acids of Serum During Development of Macaca mulatto II. During Pregnancy and Fetal Life , 1968, Pediatric Research.

[107]  G. H. Nelson,et al.  Alterations of plasma free fatty acids and glucose during labor. , 1967, American journal of obstetrics and gynecology.

[108]  H. Mendelow,et al.  CONCURRENT "ACTIVE JUVENILE CIRRHOSIS" AND "PRIMARY PULMONARY HYPERTENSION". , 1965, The American journal of medicine.

[109]  R. Naeye.  "Primary" Pulmonary Hypertension with Coexisting Portal Hypertension: A Retrospective Study of Six Cases , 1960, Circulation.

[110]  E. Craige,et al.  Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. , 1951, A.M.A. archives of pathology.

[111]  V. Mathew,et al.  The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. , 2003, Indian heart journal.

[112]  D. Rudan,et al.  [Primary pulmonary hypertension in pregnancy: case report]. , 2002, Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti.

[113]  J. W. Miller,et al.  Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. , 1998, The American journal of physiology.

[114]  C. Bose,et al.  Effect of L-arginine infusion on infants with persistent pulmonary hypertension of the newborn. , 1995, Biology of the neonate.

[115]  J. Kellum,et al.  Changes in nitric oxide precursor, L-arginine, and metabolites, nitrate and nitrite, with aging. , 1994, Life sciences.

[116]  K. Żmudka,et al.  Lack of beneficial effects of L-arginine infusion in primary pulmonary hypertension. , 1994, Wiener klinische Wochenschrift.

[117]  R. Trifiletti,et al.  Arginine deficiency accompanies persistent pulmonary hypertension of the newborn. , 1994, Biology of the neonate.

[118]  T. Lüscher,et al.  Endothelium-Derived Nitric Oxide, Endothelin, and Platelet Vessel Wall Interaction: Alterations in Hypercholesterolemia and Atherosclerosis , 1993, Seminars in thrombosis and hemostasis.

[119]  S. Moncada,et al.  The biological and pharmacological role of nitric oxide in platelet function. , 1993, Advances in experimental medicine and biology.

[120]  T. Lüscher,et al.  Endothelial dysfunction in coronary artery disease. , 1993, Annual review of medicine.

[121]  T. Gasior,et al.  Pulmonary hypertension and liver transplantation. , 1993, Anesthesiology.

[122]  T. Lüscher,et al.  Endothelium‐Dependent Regulation of Resistance Arteries: Alterations with Aging and Hypertension , 1992, Journal of cardiovascular pharmacology.

[123]  L. Zieve.  Conditional deficiencies of ornithine or arginine. , 1986, Journal of the American College of Nutrition.

[124]  W. J. Visek,et al.  Arginine needs, physiological state and usual diets. A reevaluation. , 1986, The Journal of nutrition.

[125]  D. Nair.  Primary pulmonary hypertension. , 1975, Pathologia et microbiologia.